A 28-year-old man with known HIV infection (CD4 count 150 cells/μL) presents with fever, cough, and dyspnea. Sputum smear microscopy is negative. A rapid molecular test (Xpert MTB/RIF) on sputum is positive for *M. tuberculosis* with no rifampicin resistance detected. Which investigation should be performed next to assess for drug-resistant TB and guide second-line therapy?

Explanation

## Investigation for Comprehensive Drug Susceptibility in TB-HIV Coinfection **Key Point:** Although Xpert MTB/RIF is rapid and detects rifampicin resistance, it does not assess susceptibility to isoniazid, pyrazinamide, or second-line drugs. Sputum culture with full drug susceptibility testing (DST) is essential in this immunocompromised patient to guide optimal therapy. ### Why Culture + DST is Mandatory Here **High-Yield:** In TB-HIV coinfection with low CD4 count, comprehensive DST is critical because: 1. Risk of drug-resistant TB (especially isoniazid monoresistance) is higher in HIV+ patients 2. Xpert MTB/RIF only detects rifampicin resistance; it misses isoniazid-only resistance 3. Second-line drugs (fluoroquinolones, injectable agents) require susceptibility data for optimal regimen design 4. Treatment failure risk is high with inadequate coverage ### Diagnostic Algorithm for TB-HIV Coinfection ```mermaid flowchart TD A[TB-HIV coinfection, CD4 < 200]:::outcome --> B[Xpert MTB/RIF on sputum]:::action B --> C{MTB detected?}:::decision C -->|Yes| D[Assess RIF resistance]:::action D --> E{RIF-resistant?}:::decision E -->|No| F[Send sputum for culture + full DST]:::action E -->|Yes| G[Send for culture + DST immediately]:::action F --> H[LJ or MGIT medium]:::action H --> I[DST for INH, RIF, PZA, FQ, injectables]:::action I --> J[Design regimen based on DST]:::outcome ``` **Mnemonic:** **FULL DST** = **F**luoroquinolones, **U**nderstand **L**ow CD4, **L**evels of resistance; **D**rug **S**usceptibility **T**esting mandatory. ### Comparison: Xpert MTB/RIF vs. Culture + DST | Parameter | Xpert MTB/RIF | Culture + DST | |-----------|---------------|---------------| | Time to result | 2 hours | 2–8 weeks | | Detects RIF resistance | Yes | Yes | | Detects INH resistance | No | Yes | | Detects PZA resistance | No | Yes | | Detects FQ resistance | No | Yes | | Allows speciation | No | Yes | | WHO recommendation for initial diagnosis | Yes | Confirmatory | | WHO recommendation for DST in TB-HIV | No (insufficient) | **Yes** | **Clinical Pearl:** In TB-HIV with CD4 < 200, isoniazid monoresistance is more common than in non-HIV TB. Xpert MTB/RIF will miss this, potentially leading to treatment failure if a standard 4-drug regimen is used without DST confirmation. **Warning:** Do not rely solely on Xpert MTB/RIF for treatment decisions in immunocompromised patients. Culture + DST is the standard of care for comprehensive resistance profiling.